Recent advances in omics-based research of mitral valve disease
Abstract
Mitral valve disease (MVD), particularly mitral valve prolapse (MVP), is a common heart valve condition affecting millions of people worldwide. Its pathological mechanism is complex, involving multiple factors such as extracellular matrix remodeling, inflammatory responses, and genetic susceptibility. In recent years, with the development of high-throughput sequencing and analysis technologies, omics approaches including genomics, epigenomics, transcriptomics, proteomics, metabolomics and multi-omics integration have been widely used in MVD research. These technologies have greatly deepened our understanding of the molecular basis of the disease. This review systematically organizes the scientific literature from the past decade on the use of omics technologies to study mitral valve disease, especially MVP and myxomatous mitral valve disease (MMVD). We classify the findings into genomics, epigenomics, transcriptomics, proteomics, metabolomics and multi-omics analysis. We summarize the core discoveries in each area and discuss future research directions, with the goal to provide a theoretical basis for developing new diagnostic markers and targeted therapeutic strategies.
Related
- Recent advances in research on the associations between Oxford MEST-C scores and biomarkers in IgA nephropathy
- Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
- Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies.
- Advances in artificial intelligence-driven MRI research in Alzheimer’s disease
- Multi-omics in the All Of Us Research Program expands mapping genetic mechanisms in health and disease
BibTeX
@article{jin2026recent,
title = {{Recent advances in omics-based research of mitral valve disease}},
author = {Shilin Jin and Shishi Wu and Di Zhang and Yantao Luo and Nabila Bouatia-Naji and Mengyao Yu},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = may,
doi = {10.3389/fcvm.2026.1789634},
url = {https://hal.science/hal-05793844v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Recent advances in omics-based research of mitral valve disease
AU - Shilin Jin
AU - Shishi Wu
AU - Di Zhang
AU - Yantao Luo
AU - Nabila Bouatia-Naji
AU - Mengyao Yu
PY - 2026
DA - 2026/05/15
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1789634
UR - https://hal.science/hal-05793844v1
AB - Mitral valve disease (MVD), particularly mitral valve prolapse (MVP), is a common heart valve condition affecting millions of people worldwide. Its pathological mechanism is complex, involving multiple factors such as extracellular matrix remodeling, inflammatory responses, and genetic susceptibility. In recent years, with the development of high-throughput sequencing and analysis technologies, omics approaches including genomics, epigenomics, transcriptomics, proteomics, metabolomics and multi-omics integration have been widely used in MVD research. These technologies have greatly deepened our understanding of the molecular basis of the disease. This review systematically organizes the scientific literature from the past decade on the use of omics technologies to study mitral valve disease, especially MVP and myxomatous mitral valve disease (MMVD). We classify the findings into genomics, epigenomics, transcriptomics, proteomics, metabolomics and multi-omics analysis. We summarize the core discoveries in each area and discuss future research directions, with the goal to provide a theoretical basis for developing new diagnostic markers and targeted therapeutic strategies.
SN - 2297-055X
ER -